drugset / Trial / NCT01582048
Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Phase 2
Terminated
9 enrolled
Prof. Dr. med. Wolfgang Bethge
Neovii Biotech · collabPfizer · collabmedac GmbH · collab
NaSingle-groupOpen-labelTreatment
Summary
Feasibility and toxicity of peritransplantation immunosuppression with ATG, sirolimus, mycophenolate mofetil and rituximab in patients receiving mismatched allogeneic HCT after a reduced intensity conditioning regimen with fludarabine/treosulfan
Timeline
- Start
- 2012-04
- Primary completion
- 2016-08-17
- Completion
- 2016-08-17
Outcome
Outcome not reported
Stopped (Enrollment): “slow enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fludarabine | Small molecule | 30 mg/m2 | — |
| Subject | Mycophenolate Mofetil | Small molecule | 15 mg/kg | — |
| Subject | Rituximab | Monoclonal antibody | 500 mg/m2 | — |
| Subject | Sirolimus | Small molecule | 2 mg | — |
| Subject | Treosulfan | Small molecule | 14 g | — |
| Subject | rabbit anti-thymocyte globulin | Protein / enzyme biologic | 20 mg/kg | — |